110 related articles for article (PubMed ID: 1886657)
1. Long-term effects of radiotherapy and bromocriptine treatment in patients with previous surgery for macroprolactinomas.
Moberg E; af Trampe E; Wersäll J; Werner S
Neurosurgery; 1991 Aug; 29(2):200-4; discussion 204-5. PubMed ID: 1886657
[TBL] [Abstract][Full Text] [Related]
2. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
Haase R; Jaspers C; Schulte HM; Lancranja I; Pfingsten H; Orri-Fend M; Reinwein D; Benker G
Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
[TBL] [Abstract][Full Text] [Related]
3. Prolactin decrease and shift to a normal-like isoform profile during treatment with quinagolide in a patient affected by an invasive prolactinoma.
Guido R; Valenti S; Foppiani L; De Martini D; Cossu M; Giusti M
J Endocrinol Invest; 1997 May; 20(5):289-93. PubMed ID: 9258810
[TBL] [Abstract][Full Text] [Related]
4. Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy.
Bevan JS; Adams CB; Burke CW; Morton KE; Molyneux AJ; Moore RA; Esiri MM
Clin Endocrinol (Oxf); 1987 May; 26(5):541-56. PubMed ID: 3665118
[TBL] [Abstract][Full Text] [Related]
5. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size.
van 't Verlaat JW; Croughs RJ
Clin Endocrinol (Oxf); 1991 Mar; 34(3):175-8. PubMed ID: 2036725
[TBL] [Abstract][Full Text] [Related]
6. Treatment of macroprolactinomas at Auckland Hospital 1975-91.
Wallace EA; Holdaway IM
N Z Med J; 1995 Feb; 108(994):50-2. PubMed ID: 7885646
[TBL] [Abstract][Full Text] [Related]
7. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effects of radiotherapy on macroprolactinomas using the decline rate of serum prolactin levels as a dynamic parameter.
Williams M; van Seters AP; Hermans J; Leer JW
Clin Oncol (R Coll Radiol); 1994; 6(2):102-9. PubMed ID: 8018567
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of prolactinoma with a T helper 1 activator adjuvant and autoantigens: a case report.
Hazrati SM; Aghazadeh J; Mohtarami F; Abouzari M; Rashidi A
Neuroimmunomodulation; 2006; 13(4):205-8. PubMed ID: 17337912
[TBL] [Abstract][Full Text] [Related]
10. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
Beckers A; Petrossians P; Abs R; Flandroy P; Stadnik T; de Longueville M; Lancranjan I; Stevenaert A
J Clin Endocrinol Metab; 1992 Jul; 75(1):275-80. PubMed ID: 1619019
[TBL] [Abstract][Full Text] [Related]
11. Treatments of multi-invasive giant prolactinoma.
Yang MY; Shen CC; Ho WL
J Clin Neurosci; 2004 Jan; 11(1):70-5. PubMed ID: 14642373
[TBL] [Abstract][Full Text] [Related]
12. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
13. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
14. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
16. Macroprolactinomas with suprasellar extension: effect of bromocriptine withdrawal during one or more pregnancies.
Ahmed M; al-Dossary E; Woodhouse NJ
Fertil Steril; 1992 Sep; 58(3):492-7. PubMed ID: 1521641
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment of invasive giant prolactinomas.
Yu C; Wu Z; Gong J
Pituitary; 2005; 8(1):61-5. PubMed ID: 16411070
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
van der Lely AJ; Brownell J; Lamberts SW
J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
[TBL] [Abstract][Full Text] [Related]
19. Parlodel LAR in the treatment of macroprolactinomas.
Kocijancic A; Prezelj J; Vrhovec I; Lancranjan I
Acta Endocrinol (Copenh); 1990 Feb; 122(2):272-6. PubMed ID: 2316314
[TBL] [Abstract][Full Text] [Related]
20. A case of large prolactinoma supposed to be cured by bromocriptine therapy.
Arita K; Uozumi T; Ohta M
Endocrinol Jpn; 1988 Jun; 35(3):503-9. PubMed ID: 3197661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]